AASK-CO

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK Clinical trial. Howard University will enroll 29 in the AASK Cohort Study. Additionally, those AASK participants who reached ESRD will be invited to attend one visit for collection of DNA. Exposures to be collected twice/year including environmental, genetic, physiologic and socioeconomic factors. The primary outcome will be defined by the doubling of serum creatinine, progression to ESRD or death. Appropriate antihypertensive treatment will be provided to participants who do not have ESRD. In this fashion, the Cohort will directly control two of the major "known" determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medications) and will, therefore, address its research objectives in the setting of recommended hypertensive care. 4-6 contacts for BP control will take place per year for each participant. The duration of followup in the Cohort Study will be 5 years. The AASK Cohort Study will provide data that enhances our understanding of the processes that determine progression of renal disease. Furthermore, data from this study might ultimately lead to new prevention strategies that delay or prevent the onset of ESRD. The primary objective is to prospectively determine the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease who receive recommended antihypertension therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease.